Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

• Status: Not yet recruiting
• Trial end date: 2026-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral blood cells from treated and control subjects will be compared for mitochondrial respiratory function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant & anti-electrophile genes.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Texas Tech University Health Sciences Center
• Treatments: Sulforaphane

Criteria

Inclusion Criteria:

• Age > 60 years

• Diagnosis of HFpEF (HF symptoms with a normal EF (>/=50 %)

• Ability to walk more than 500 feet (by self-report)

• Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study

Exclusion Criteria:

• Inability to provide informed consent

• Diagnosis of active cancer

• Inability to read and understand the SF-36 in English

• Participants using over the counter antioxidant supplements

• Participants with pulmonary or other issues which restrict walking capacity

• On oxygen therapy